A Phase 1, Open-label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 in Patients With Unresectable, Recurrent, Locally-advanced, or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs UCB 6352 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Syndax Pharmaceuticals
- 02 Mar 2017 According to a Syndax Pharmaceuticals media release, company expects to present data at a scientific congress in the fourth quarter of 2017.
- 10 Nov 2016 Status changed from planning to recruiting, according to a Syndax Pharmaceuticals media release.
- 09 Aug 2016 According to a Syndax Pharmaceuticals media release, the company anticipates to initiate dosing in this trial later in the year 2016.